$BTSG · BrightSpring Health Services, Inc.
BrightSpring Health Services filed its Q3 2026 10-Q, reporting total revenues of $4.213B (+26.4% YoY), GAAP diluted EPS of $0.45, and net income of $100.1M. Operating income nearly doubled to $160.5M from $87.8M in the prior-year quarter, driven by a 33.8% revenue surge in Specialty & Infusion Pharmacy.
- Q3 revenue hit $4.213B, up 26.4% YoY, driven by Specialty & Infusion Pharmacy volume (+33.8%)
- Operating income nearly doubled to $160.5M from $87.8M in Q3 2025
- GAAP diluted EPS from continuing operations rose to $0.46 vs $0.17 a year ago
- Pharmacy Solutions gross profit per script jumped 26.8% to $28.86 on favorable drug mix
- Cash and equivalents swelled to $717.8M from $88.4M at year-end 2025, aided by discontinued ops sale
Extended-hours trading shows BTSG at $64.50, up 7.11% from the regular close and 8.48% above the filing-time price, signaling strong positive reception to the revenue surge and operating leverage.
A 26.4% revenue surge and near-doubling of operating income at an $11.9B healthcare services company signals powerful operating leverage from specialty drug mix shift.
BrightSpring's Specialty & Infusion Pharmacy segment is benefiting from the same specialty drug utilization tailwinds lifting peers like Cencora and McKesson, while its Home & Community Pharmacy faces IRA headwinds compressing traditional pharmacy margins industry-wide.
Home & Community Pharmacy revenue declined 6.3% due to Inflation Reduction Act impacts including mandatory Medicare drug price negotiations and rebates. The company carries $2.18B in total debt and $40.9M in accumulated goodwill impairment from 2022.